Clinical trials: Retinal Vascular Disorder
AMD, nAMD
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ATMOSPHERE (NCT04704921)
- Testing
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Where
- 89 sites in United States
- Volunteers
- 671 people
- Sponsor
- AbbVie
Diabetic Retinopathy (DR)
Preliminary Assessment of an Automated Tool for Diabetic Retinopathy Screening
This study is being done to evaluate the performance of a software that uses artificial intelligence to analyze photographs of the retina to help detect diabetic retinopathy.
- Trial name
- NCT07404657
- Testing
- automatic analysis of fundus images performed by the software tool based on artificial intelligence
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Centervue SpA
Diabetic Neuropathies, Diabetic Foot
Thermal Screening for Early Diabetic Peripheral Neuropathy (DPN)
The goal of this research is to develop better tools for diagnosing illness of the feet and legs of people who have diabetes. Investigators will use thermal videos of the foot to aid in the refinement of a system designed to…
- Conditions
- Diabetic Neuropathies, Diabetic Foot, Diabetic Retinopathy
- Trial name
- NCT03069729
- Testing
- no intervention
- Where
- United States
- Volunteers
- 331 people, healthy volunteers welcome
- Sponsor
- VisionQuest Biomedical LLC
Diabetic Macular Edema
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with DME.
- Trial name
- MIVI-II (NCT00412451)
- Testing
- ocriplasmin
- Where
- 15 sites in Belgium, Germany and 4 more
- Volunteers
- 51 people
- Sponsor
- ThromboGenics
Neovascular Age-Related Macular Degeneration
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid…
- Trial name
- SWIFT (NCT04264819)
- Testing
- RTH258/Brolucizumab
- Where
- 51 sites in France
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema, Diabetic Retinopathy
ADVM-022 Intravitreal Gene Therapy for DME
A Phase 2, Multi-Center, Randomized, Double-Masked*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema [INFINITY]
- Trial name
- INFINITY (NCT04418427)
- Testing
- 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- Adverum Biotechnologies, Inc.
Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration
The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
The study will assess the safety and efficacy of Everolimus (RAD001) alone or in combination with Lucentis in patients with neo-vascular age related macular degeneration (AMD)
- Trial name
- NCT00857259
- Testing
- Everolimus, Ranibizumab
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Macular Degeneration
Evaluation of the Retinal Health Monitoring System Thickness Module
Evaluate the ability and accuracy of the Retinal Health Monitoring System - Retinal Thickness Module (RHMS - RTM).
- Trial name
- NCT04499703
- Testing
- RHMS-RTM, SD-OCT
- Where
- Switzerland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kubota Vision Inc.
Retinal Vein Occlusion
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
To determine the efficacy of vascular endothelial growth factor (VEGF) Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion
- Trial name
- GALILEO (NCT01012973)
- Testing
- Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
- Where
- 73 sites in Australia, Austria and 8 more
- Volunteers
- 177 people
- Sponsor
- Bayer
Age-Related Macular Degeneration, Polypoid Choroidal Vasculopathy
Adjunct Episcleral Brachytherapy for PCV
This study is investigating the use of episcleral brachytherapy (ESB) adjunct to aflibercept compared to aflibercept monotherapy for the treatment of polyploid choroidal vasculopathy (PCV) in patients experiencing an inadequate…
- Trial name
- KILAUEA (NCT05251636)
- Testing
- Episcleral Brachytherapy, Aflibercept Injection
- Volunteers
- 159 people
- Sponsor
- Salutaris Medical Devices, Inc.
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
The Farseeing Study will explore long-term effectiveness, safety, and treatment patterns among patients being treated with faricimab in real-world, routine clinical practice in China.
- Conditions
- Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
- Trial name
- NCT06439576
- Testing
- Faricimab
- Where
- 41 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
Diffuse Diabetic Macular Edema
Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema
The goal of the study is to evaluate the safety and tolerability of 4 different doses of iCo-007 Intravitreal Injection in patients with diffuse diabetic macular edema.
- Trial name
- NCT00886808
- Testing
- iCo-007 Intravitreal Injection
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- iCo Therapeutics Inc.
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
This study is conducted to evaluate the safety of a single intravitreal injection of THR-687.
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT03666923
- Testing
- THR-687 dose level 1, THR-687 dose level 2, THR-687 dose level 3
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- ThromboGenics
Retinal Vein Occlusion
Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO
Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
- Trial name
- NCT02387788
- Testing
- AKB-9778
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Aerpio Therapeutics
Diabetic Retinopathy, Diabetic Eye Problems
Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool
More than 29 million people in the US are living with diabetes, many of whom will develop diabetic retinopathy (DR) or diabetic macular edema (DME) collectively known as diabetic eye disease (DED), the leading cause of vision…
- Conditions
- Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
- Trial name
- NCT03112005
- Testing
- Color fundus photography, Mydriatic Agent
- Where
- United States
- Volunteers
- 942 people
- Sponsor
- Eyenuk, Inc.
Diabetes Mellitus, Diabetic Retinopathy
A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)
This study will evaluate the safety and efficacy of AG-014699 in diabetic patients
- Trial name
- NCT00457470
- Testing
- AG-014699
- Sponsor
- Pfizer
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG)
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
- Conditions
- Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
- Trial name
- (PENGUIN) (NCT07354477)
- Testing
- QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Qlaris Bio, Inc.
Diabetic Retinopathy, Diabetic Macular Edema
PROTECT2: Diabetes Care - Eye Exam
The PROTECT2 pilot study is a single cohort prospective study to gather pilot data and finalize operational details of the main study.
- Trial name
- NCT03094819
- Testing
- Financial Incentive, Retinal Care DR
- Where
- United States
- Volunteers
- 4,500 people
- Sponsor
- Retinal Care Inc.
Macular Edema, Retinal Vein Occlusion
Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China
This study will take place in China to evaluate the safety and efficacy of OZURDEX implant 700 μg in the treatment of macular edema due to retinal vein occlusion (RVO) in patients who have never received treatment for RVO.
- Trial name
- NCT03908307
- Testing
- OZURDEX
- Where
- 9 sites in China
- Volunteers
- 150 people
- Sponsor
- Allergan
Diabetic Retinopathy
AutoDx-DR Prospective Clinical Validation Study Protocol
In this study, we will prospectively evaluate the accuracy of a deep-learning based software algorithm in the detection of diabetic retinopathy from 60° wide single-field retinal fundus images.
- Trial name
- NCT04627272
- Testing
- AutoDX-DR
- Volunteers
- 1,539 people
- Sponsor
- Hill-Rom